Bradykinin antagonists modified with dipeptide mimetic beta-turn inducers
Maria C Alcaro1, Valerio Vinci, Anna M D'Ursi
1Laboratory of Peptide and Protein Chemistry and Biology, Dipartimento di Chimica Organica, University of Firenze and CNR-ICCOM, Polo Scientifico, Via della Lastruccia 13, I-50019 Sesto Fiorentino (FI), Italy.
Bioorganic & Medicinal Chemistry Letters
|March 1, 2006
Summary
Researchers developed novel bradykinin (BK) antagonists by modifying peptide structures. These new compounds, featuring constrained dipeptides, show potential for treating BK-related conditions.
Area of Science:
- Medicinal Chemistry
- Peptide Science
- Pharmacology
Background:
- Bradykinin (BK) plays a significant role in numerous pathophysiological processes.
- Developing potent BK antagonists is crucial for therapeutic interventions.
- Constrained unnatural amino acids are key to inducing specific secondary structures in peptide antagonists.
Purpose of the Study:
- To investigate structure-activity relationships of bradykinin B2 antagonists.
- To explore the efficacy of conformationally constrained dipeptide mimetics as beta-turn inducers.
- To synthesize and evaluate novel peptide analogues of the potent B2 antagonist HOE 140.
Main Methods:
- Structure-activity relationship (SAR) study.
- Synthesis of two peptide analogues of HOE 140.
- Replacement of the D-Tic-Oic dipeptide with conformationally constrained beta-turn inducers.
Main Results:
- The study reports the synthesis and evaluation of novel peptide analogues.
- The modified peptides incorporate conformationally constrained dipeptide mimetics.
- These modifications aim to enhance the secondary structure and antagonistic properties.
Conclusions:
- Conformationally constrained dipeptide mimetics can be effectively used in designing potent BK antagonists.
- The replacement of specific dipeptides can lead to analogues with potentially improved therapeutic profiles.
- Further research into these modified peptide structures could yield new therapeutic agents for BK-mediated diseases.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...